Development of pharmacological postconditioning against liver ischemia reperfusion injury, and clarification of mechanisms
| Project/Area Number |
19591805
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Anesthesiology/Resuscitation studies
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
CHO Sungsam Nagasaki University, 病院, 講師 (90325655)
|
|---|
| Project Period (FY) |
2007 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 肝臓 / 虚血再灌流 / ポストコンディショニング / ホスホジエステラーゼ阻害薬 / Rhoキナーゼ阻害薬 / PDEIII阻害薬 / 虚血再灌流障害 / PI3-Akt / ERK / RISK pathway / eNOS |
|---|
| Research Abstract |
We showed that both phosphodiesterase III inhibitors and Rho kinase inhibitors administered just before reperfusion protect against liver ischemia reperfusion injury and apoptosis. This protective effect was attenuated by wortmannin, a PI3K-Akt inhibitor, PD-98059, an ERK inhibitor, or L-NAME, a eNOS inhibitor. Both phosphodiesterase III inhibitors and Rho kinase inhibitors administered just before reperfusion activated PI3K-Akt, ERK, or eNOS. Thus both phosphodiesterase III inhibitors and Rho kinase inhibitors could have postconditioning effects via PI3K-Akt, ERK, or eNOS activation.
|
Report
(6 results)
Research Products
(20 results)
